Followers | 9 |
Posts | 1778 |
Boards Moderated | 0 |
Alias Born | 05/20/2010 |
Thursday, July 22, 2010 5:00:32 PM
Analysts at Jefferies & Co reiterate their "hold" rating on Verenium Corp (NASDAQ: VRNM), while raising their estimates for the company. The target price for VRNM has been reduced from $3.60 to $2.90.
According to Jefferies & Co, “Verenium has laid out a framework for developing its core enzyme business. These include: 1/ Organization (streamlining the business); 2/ Transition out of San Diego facility (and establish a new fermentation lab); 3) Manufacturing improvements (projects to decrease costs of and variability in production, i.e. debottlenecking); 4/ Capacity additions (the company currently has enough scale in its facility to meet market needs for all of its commercial enzymes but may add capacity in the medium-term to meet growing demand; a 1m L greenfield enzyme facility would require ~$100m capital); 5/ Invest in the pipeline (Verenium currently has 15 specific biomolecules that are in various stages of development).”
“Verenium has retained its entire regulatory staff which has extensive experience in registering products with the U.S. EPA, FDA, Center for Veterinary Medicine and other global Agencies,” the analysts add.
Jefferies has raised its EPS estimate for FY10 from -$3.00 to -$2.26.
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM